DLL3 and small cell lung carcinoma: There was no significant difference in median overall survival from SCLC diagnosis for evaluable patients with non-missing data based on DLL3 expression (negative DLL3 expression (n = 139), 9.5 months; positive DLL3 expression (n = 747), 9.5 months; all evaluable patients (n = 893, 9.5 months) [13].